Expanded Facility Supports Business and Clinical Operations to Drive Future Pivotal Study of ALZ-801 in Patients with Alzheimer’s Disease
FRAMINGHAM, Mass., April 8, 2015 — Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that it has established its headquarters in a newly renovated facility located in Framingham, Mass. Alzheon’s new offices in Framingham will support the growth in the business, product development and clinical operations driven by clinical development of ALZ-801, an oral, first-in-class, small molecule inhibitor of amyloid formation and neurotoxicity for the treatment of Alzheimer’s disease. Alzheon is advancing ALZ-801 toward initiation of a potential pivotal clinical study in Alzheimer’s disease in the near future.
“Our new headquarters will enable us to considerably expand our capabilities and accelerate our product development. This new facility will provide us with the flexibility to accommodate our future growth, as we make progress toward our goal of advancing our oral amyloid-targeting ALZ-801 drug candidate in patients with Alzheimer’s disease,” said Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer of Alzheon. “We have built a world-class team and board of directors, as well as a robust foundation of data on ALZ-801 that position us to efficiently execute on our strategy to build Alzheon as a company that will bring transformational treatments to patients with Alzheimer’s disease and other neurological disorders in the near future.”
The new facility increases Alzheon’s capacity in a highly desirable location that enables the company to accelerate its growth and ability to attract a highly-skilled team of scientists, clinicians, and business professionals. The new site allows Alzheon to easily engage with the world class biotechnology resources in the Boston biotechnology hub. In this facility, Alzheon will be located adjacent to Massachusetts Turnpike, Interstate Route 90, readily accessible from Logan Airport in Boston, Mass. Alzheon’s new address is 111 Speen Street, Suite 306, Framingham, Mass., 01701.
Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ‐801, is a first‐ in‐class, oral inhibitor of amyloid aggregation and neurotoxicity—hallmarks of Alzheimer’s disease. ALZ‐ 801 is an optimized, novel prodrug that builds on the established safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to apply our discovery platform and development experience to unlock new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders.
The Yates Network